Antara Capital’s Ginkgo Bioworks DNA Stock Holding History

Antara Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,000	Closed	-$2.32M	–	240
2021 Q3	$2.32M	Buy	+5,000	New	+$2.43M	0.18%	82

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Antara Capital's DNA Position: Q4 2021 in Review

Antara Capital sold out of Ginkgo Bioworks (DNA) in Q4 2021, closing a stake of 5,000 shares — an estimated $2.32M sold.

Antara Capital first reported a position in DNA in Q3 2021 and held it in 1 quarter. The position peaked at $2.32M in Q3 2021. 164 funds tracked by Wall St. Rank hold DNA as of Q4 2021.

Antara Capital reported no remaining Ginkgo Bioworks position as of Q4 2021 after selling out during the quarter.
Antara Capital sold 5,000 Ginkgo Bioworks shares in Q4 2021, an estimated $2.32M.
Antara Capital first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 1 quarter.
Antara Capital's Ginkgo Bioworks position peaked at $2.32M in Q3 2021.
164 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2021.

Based on Antara Capital's 13F filing for Q4 2021, filed 14 Feb 2022.